• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种用于铅同位素203Pb和212Pb的新型双功能螯合剂的合成、表征及评估。

Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb.

作者信息

Chappell L L, Dadachova E, Milenic D E, Garmestani K, Wu C, Brechbiel M W

机构信息

Radioimmune and Inorganic Chemistry Section, ROB, DCS, Bethesda, Maryland 20892-1002, USA.

出版信息

Nucl Med Biol. 2000 Jan;27(1):93-100. doi: 10.1016/s0969-8051(99)00086-4.

DOI:10.1016/s0969-8051(99)00086-4
PMID:10755652
Abstract

Radioisotopes of Pb(II) have been of some interest in radioimmunotherapy and radioimmunoimaging (RII). However, the absence of a kinetically stable bifunctional chelating agent for Pb(II) has hampered its use for these applications. 203Pb (T(1/2) = 52.02 h) has application potential in RII, with a gamma-emission that is ideal for single photon emission computerized tomography, whereas 212Pb (T(1/2) = 10 h) is a source of highly cytotoxic alpha-particles via its decay to its 212Bi (T(1/2) = 60 min) daughter. The synthesis of the novel bifunctional chelating agent 2-(4-isothiocyanotobenzyl)-1,4,7,10-tetraaza-1,4,7,10-tetra- (2-carbamoyl methyl)-cyclododecane (4-NCS-Bz-TCMC) is reported herein. The Pb[TCMC]2+ complex was less labile to metal ion release than Pb[DOTA]2- at pH 3.5 and below in isotopic exchange experiments. In addition to increased stability to Pb2+ ion release at low pH, the bifunctional TCMC ligand was found to have many other advantages over the bifunctional 1,4,7,10-tetraazacyclodocane-1,4,7,10-tetraacetic acid (DOTA) ligand. These include a shorter and more straightforward synthetic route, a more efficient conjugation reaction to a monoclonal antibody (mAb), with a higher chelate to protein ratio, a higher percent immuroreactivity, and a more efficient radiolabeling reaction of the mAb-ligand conjugate with 203Pb.

摘要

铅(II)的放射性同位素在放射免疫治疗和放射免疫显像(RII)中受到了一定关注。然而,缺乏一种动力学稳定的用于铅(II)的双功能螯合剂阻碍了其在这些应用中的使用。203Pb(半衰期T(1/2)=52.02小时)在RII中具有应用潜力,其γ发射非常适合单光子发射计算机断层扫描,而212Pb(半衰期T(1/2)=10小时)通过衰变产生其212Bi(半衰期T(1/2)=60分钟)子体,是一种高细胞毒性α粒子的来源。本文报道了新型双功能螯合剂2-(4-异硫氰酸苄基)-1,4,7,10-四氮杂-1,4,7,10-四(2-氨甲酰甲基)-环十二烷(4-NCS-Bz-TCMC)的合成。在同位素交换实验中,在pH 3.5及以下时,Pb[TCMC]2+络合物比Pb[DOTA]2-对金属离子释放的稳定性更低。除了在低pH下对Pb2+离子释放具有更高的稳定性外,还发现双功能TCMC配体比双功能1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸(DOTA)配体具有许多其他优点。这些优点包括合成路线更短、更直接,与单克隆抗体(mAb)的偶联反应更高效,螯合物与蛋白质的比例更高,免疫反应性百分比更高,以及mAb-配体缀合物与203Pb的放射性标记反应更高效。

相似文献

1
Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb.一种用于铅同位素203Pb和212Pb的新型双功能螯合剂的合成、表征及评估。
Nucl Med Biol. 2000 Jan;27(1):93-100. doi: 10.1016/s0969-8051(99)00086-4.
2
Improved synthesis of the bifunctional chelating agent 1,4,7,10-tetraaza-N-(1-carboxy-3-(4-nitrophenyl)propyl)-N',N'',N'''-tri s(acetic acid)cyclododecane (PA-DOTA).双功能螯合剂1,4,7,10-四氮杂-N-(1-羧基-3-(4-硝基苯基)丙基)-N',N'',N'''-三(乙酸)环十二烷(PA-DOTA)的改进合成方法。
Bioorg Med Chem. 1999 Nov;7(11):2313-20. doi: 10.1016/s0968-0896(99)00171-6.
3
Synthesis, conjugation, and radiolabeling of a novel bifunctional chelating agent for (225)Ac radioimmunotherapy applications.用于(225)锕放射免疫治疗应用的新型双功能螯合剂的合成、共轭和放射性标记。
Bioconjug Chem. 2000 Jul-Aug;11(4):510-9. doi: 10.1021/bc990153f.
4
The use of 212Pb-labeled monoclonal antibody in the treatment of murine erythroleukemia.212Pb标记的单克隆抗体在小鼠红白血病治疗中的应用。
Int J Radiat Oncol Biol Phys. 1996 Feb 1;34(3):609-16. doi: 10.1016/0360-3016(95)02119-1.
5
Maleimidocysteineamido-DOTA derivatives: new reagents for radiometal chelate conjugation to antibody sulfhydryl groups undergo pH-dependent cleavage reactions.马来酰亚胺半胱氨酸酰胺 - DOTA衍生物:用于将放射性金属螯合物与抗体巯基结合的新型试剂会发生pH依赖性裂解反应。
Bioconjug Chem. 1998 Jan-Feb;9(1):72-86. doi: 10.1021/bc970136v.
6
New synthesis of phenyl-isothiocyanate C-functionalised cyclams. Bioconjugation and (64)Cu phenotypic PET imaging studies of multiple myeloma with the te2a derivative.苯基异硫氰酸酯C-官能化环胺的新合成方法。用te2a衍生物对多发性骨髓瘤进行生物共轭和(64)Cu表型PET成像研究。
Org Biomol Chem. 2015 Dec 14;13(46):11302-14. doi: 10.1039/c5ob01618e.
7
Synthesis and evaluation of a macrocyclic bifunctional chelating agent for use with bismuth radionuclides.一种用于铋放射性核素的大环双功能螯合剂的合成与评价。
Nucl Med Biol. 2001 May;28(4):409-18. doi: 10.1016/s0969-8051(00)00203-1.
8
Synthesis and Evaluation of Bifunctional [2.2.2]-Cryptands for Nuclear Medicine Applications.双功能[2.2.2]穴醚的合成与评价及其在核医学中的应用。
Inorg Chem. 2021 Jul 5;60(13):10030-10037. doi: 10.1021/acs.inorgchem.1c01274. Epub 2021 Jun 23.
9
Synthesis of 2-(p-thiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid: application of the 4-methoxy-2,3,6-trimethylbenzenesulfonamide protecting group in the synthesis of macrocyclic polyamines.
Bioconjug Chem. 1993 May-Jun;4(3):236-45. doi: 10.1021/bc00021a009.
10
Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1.使用铅-212-DOTA-AE1对卵巢肿瘤上的HER2/neu癌蛋白进行放射免疫治疗。
J Nucl Med. 1997 Dec;38(12):1944-50.

引用本文的文献

1
Pb in targeted radionuclide therapy: a review.靶向放射性核素治疗中的铅:综述
EJNMMI Radiopharm Chem. 2025 Jul 1;10(1):34. doi: 10.1186/s41181-025-00362-7.
2
Side-by-Side Comparison of the In Vivo Performance of [Pb]Pb-DOTAMTATE and Other SSTR2-Targeting Compounds.[铅]铅-DOTAMTATE与其他SSTR2靶向化合物体内性能的并排比较。
J Nucl Med. 2025 Mar 3;66(3):391-397. doi: 10.2967/jnumed.124.268345.
3
Targeted radiopharmaceuticals: an underexplored strategy for ovarian cancer.靶向放射性药物:卵巢癌研究不足的策略。
Theranostics. 2024 Sep 30;14(16):6281-6300. doi: 10.7150/thno.99782. eCollection 2024.
4
Theoretical Study of Metal-Ligand Interactions in Lead Complexes with Radiopharmaceutical Interest.具有放射性药物应用价值的铅配合物中金属-配体相互作用的理论研究。
Molecules. 2024 Sep 4;29(17):4198. doi: 10.3390/molecules29174198.
5
Antibody Drug Conjugates for Cancer Therapy: From Metallodrugs to Nature-Inspired Payloads.抗体药物偶联物在癌症治疗中的应用:从金属药物到受自然启发的有效载荷。
Int J Mol Sci. 2024 Aug 8;25(16):8651. doi: 10.3390/ijms25168651.
6
Exploration of commercial cyclen-based chelators for mercury-197 m/g incorporation into theranostic radiopharmaceuticals.探索用于将汞-197m/g掺入治疗诊断用放射性药物的基于商业环醚的螯合剂。
Front Chem. 2024 Feb 8;12:1292566. doi: 10.3389/fchem.2024.1292566. eCollection 2024.
7
[Pb]Pb-eSOMA-01: A Promising Radioligand for Targeted Alpha Therapy of Neuroendocrine Tumors.[铅]Pb-eSOMA-01:一种用于神经内分泌肿瘤靶向α治疗的有前景的放射性配体。
Pharmaceuticals (Basel). 2023 Jul 10;16(7):985. doi: 10.3390/ph16070985.
8
Organotrifluoroborate enhances tumor targeting of fibroblast activation protein inhibitors for targeted radionuclide therapy.三氟硼酸盐增强成纤维细胞激活蛋白抑制剂的肿瘤靶向性用于放射性核素靶向治疗。
Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2636-2646. doi: 10.1007/s00259-023-06230-3. Epub 2023 Apr 27.
9
Probing Unexpected Reactivity in Radiometal Chemistry: Indium-111-Mediated Hydrolysis of Hybrid Cyclen-Hydroxypyridinone Ligands.探究放射金属化学中的意外反应性:铟-111 介导的杂环轮烷-羟基吡啶酮配体的水解。
Inorg Chem. 2023 Apr 3;62(13):5270-5281. doi: 10.1021/acs.inorgchem.3c00353. Epub 2023 Mar 17.
10
Targeted alpha therapy with the Ra/Pb-TCMC-TP-3 dual alpha solution in a multicellular tumor spheroid model of osteosarcoma.在骨肉瘤多细胞肿瘤球体模型中使用Ra/Pb-TCMC-TP-3双α溶液进行靶向α治疗。
Front Med (Lausanne). 2022 Nov 23;9:1058863. doi: 10.3389/fmed.2022.1058863. eCollection 2022.